Neurocrine BiosciencesFRA:NB3 +0.23%94 Current Ratio is 2.93 as of Mar. 2026, which is 29% below its 10-year median of 4.11. GuruFocus rates FRA:NB3 with a GF Score™ of 94/100 and a GF Value™ of €163.30 (Fairly Valued). The stock has 6 warning signs investors should review. Among 998 Drug Manufacturers companies, Neurocrine Biosciences ranks better than 66.43% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Neurocrine Biosciences's current ratio for the quarter that ended in Mar. 2026 was 2.93.
Neurocrine Biosciences has a current ratio of 2.93. It generally indicates good short-term financial strength.
The historical rank and industry rank for Neurocrine Biosciences's Current Ratio or its related term are showing as below:
FRA:NB3'
s Current Ratio Range Over the Past 10 Years
Min: 1.47 Med: 4.11 Max: 19.36
Current: 2.93
During the past 13 years, Neurocrine Biosciences's highest Current Ratio was 19.36. The lowest was 1.47. And the median was 4.11.
FRA:NB3's Current Ratio is ranked better than 66.43% of 998
companies
in the Drug Manufacturers industry
Industry Median: 2
vs FRA:NB3: 2.93
Neurocrine Biosciences (FRA:NB3) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Neurocrine Biosciences Current Ratio Related Terms
Neurocrine Biosciences Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:NB3 vs VTRS, ELAN, UTHR: Current Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Neurocrine Biosciences's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neurocrine Biosciences Current Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Neurocrine Biosciences's Current Ratio distribution charts can be found below:
* The bar in red indicates where Neurocrine Biosciences's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neurocrine Biosciences (FRA:NB3) has a Current Ratio of 2.93 as of Mar. 2026. This is 29% below median its historical median of 4.11. Over the past decade, Neurocrine Biosciences' Current Ratio has ranged from 1.47 to 19.36. According to the industry distribution chart, Neurocrine Biosciences ranks #335 out of 998 companies in the Drug Manufacturers industry, placing it in the top 33.6%.
Is Neurocrine Biosciences' Current Ratio too high?
Neurocrine Biosciences' current Current Ratio of 2.93 is 29% below median its 10-year median of 4.11. Over the past 10 years, this metric has ranged from a low of 1.47 to a high of 19.36. The Drug Manufacturers industry median Current Ratio is 2.00. Neurocrine Biosciences' value of 2.93 is 46.5% above this industry median. Based on the distribution chart, Neurocrine Biosciences ranks #335 out of 998 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Neurocrine Biosciences has a GF Score™ of 94/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Neurocrine Biosciences' Current Ratio compare to VTRS and ELAN?
According to the Drug Manufacturers industry distribution chart, Neurocrine Biosciences ranks #335 out of 998 companies for Current Ratio. This puts Neurocrine Biosciences in the upper half of its industry. The industry median Current Ratio is 2.00. Neurocrine Biosciences' value of 2.93 is 46.5% above this benchmark. Historically, Neurocrine Biosciences' own Current Ratio has ranged from 1.47 to 19.36 over the past decade. While the company's 10-year median is 4.11 vs. the industry median of 2.00, Neurocrine Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 2.00, based on 998 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Neurocrine Biosciences's current Current Ratio of 2.93 is 46.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neurocrine Biosciences's current Current Ratio is 2.93, which is 29% below median its own 10-year median of 4.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neurocrine Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Neurocrine Biosciences (FRA:NB3) is currently considered Fairly Valued. The stock's GF Value™ is €163.30, compared to a current price of €153.55 — trading 6% below its estimated fair value. The current Current Ratio is 2.93, which is 29% below median its 10-year median of 4.11 and 46.5% above the Drug Manufacturers industry median of 2.00. Neurocrine Biosciences' overall GF Score™ is 94/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Neurocrine Biosciences (FRA:NB3), the current Current Ratio is 2.93 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Neurocrine Biosciences (FRA:NB3) Overvalued in 2026?
Based on GuruFocus' analysis, Neurocrine Biosciences stock appears to be undervalued.
The current stock price of €153.55 is trading 6% below its estimated GF Value™ of €163.30.
GuruFocus considers Neurocrine Biosciences to be Fairly Valued.
Key valuation signals for FRA:NB3:
Current Ratio: 2.93 (29% below median its 10-year median of 4.11)
GF Value™: €163.30 vs. price of €153.55 (6% below fair value)
Industry Position: 46.5% above the Drug Manufacturers median (#335 of 998)
No single metric tells the full story. See the FRA:NB3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
94GF Score
Get the complete analysis for FRA:NB3
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:NB3 has been successfully added to your 
